Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 7, 2008, Pages 695-700

  Van Gestel, Yvette R B M ^a   Hoeks, Sanne E ^a   Sin, Don D ^b   Welten, Gijs M J M ^a   Schouten, Olaf ^a   Witteveen, Han J ^a   Simsek, Cihan ^a   Stam, Henk ^a   Mertens, Frans W ^a   Bax, Jeroen J ^c   Van Domburg, Ron T ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adrenergic blocking agents; Chronic obstructive pulmonary disease; Peripheral arterial disease; Vascular surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOSELECTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SPIROMETRY; VASCULAR SURGERY; DRUG INCOMPATIBILITY; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; RISK; SURVIVAL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; DRUG INCOMPATIBILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 52749097999     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200803-384OC     Document Type: Article

References (39)

1. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713-1720.
2. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-1794.
3. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven LL, Scheffer MG, Trocino G, Vigna C, Baars HF, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001;22:1353-1358.
4. Schouten O, Shaw LJ, Boersma E, Bax JJ, Kertai MD, Feringa HH, Biagini E, Kok NF, Urk H, Elhendy A, et al. A meta-analysis of safety and effectiveness of perioperative beta-blocker use for the prevention of cardiac events in different types of noncardiac surgery. Coron Artery Dis 2006;17:173-179.
5. Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002;287:1435-1444.
6. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2007;116:e418-e499.
7. Centers for Disease Control. The Surgeon General's 1989 report on reducing the health consequences of smoking: 25 years of progress. MMWR Morb Mortal Wkly Rep 1989;38:1-32.
8. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
9. Wellstein A, Palm D, Belz GG, Butzer R, Polsak R, Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J 1987;8(Suppl M):3-8.
10. Ashrafian H, Violaris AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: The pro viewpoint. Prim Care Respir J 2005;14:236-241.
11. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;CD003566.
12. Camsari A, Arikan S, Avan C, Kaya D, Pekdemir H, Cicek D, Kiykim A, Sezer K, Akkus N, Alkan M, et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003;18:188-192.
13. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
14. Kieran SM, Cahill RA, Browne I, Sheehan SJ, Mehigan D, Barry MC. The effect of perioperative beta-blockade on the pulmonary function of patients undergoing major arterial surgery. Eur J Vasc Endovasc Surg 2006;32:305-308.
15. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-1956.
16. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004;44:497-502.
17. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002;137:715-725.
18. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-305.
19. Feringa HH, Bax JJ, Boersma E, Kertai MD, Meij SH, Galal W, Schouten O, Thomson IR, Klootwijk P, van Sambeek MR, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006;114:I344-I349.
20. van Gestel YRBM, Hoeks SE, Welten GMJM, Schouten O, Stam H, Mertens FW, van Domburg RT, van Sambeek MRHM, Goei D, Poldermans D. Beta-blockers in patients with chronic obstructive pulmonary disease and atherosclerosis: from contraindication to indication? Eur Heart J 2007;28(Abstract Suppl):214.
21. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
23. Subbarao P, Lebecque P, Corey M, Coates AL. Comparison of spirometric reference values. Pediatr Pulmonol 2004;37:515-522.
24. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003;97:1094-1101.
25. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications. Am Heart J 2008;155:521-525.
26. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239.
27. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339.
28. Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001;164:597-601.
29. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-353.
30. Sakamaki F, Oya H, Nagaya N, Kyotani S, Satoh T, Nakanishi N. Higher prevalence of obstructive airway disease in patients with thoracic or abdominal aortic aneurysm. J Vasc Surg 2002;36:35-40.
31. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-1889.
32. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27.
33. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005;26:2259-2268.
34. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-2816.
35. Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJ, Poole-Wilson PA, Flather MD. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109-115.
36. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Eur Heart J 2003;24:552-559.
37. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-498.
38. Woolcock AJ, Anderson SD, Peat JK, Du Toit JI, Zhang YG, Smith CM, Salome CM. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438-1443.
39. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001;17:380-385.